New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
07:39 EDTCYTKCytokinetics completes patient enrollment in third cohort of AROMIC-AHF
Cytokinetics announced that ATOMIC-AHF has completed patient enrollment in its third and final cohort. ATOMIC-AHF, or Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure, is a Phase IIb clinical trial designed to evaluate the safety, tolerability and efficacy of an intravenous formulation of omecamtiv mecarbil compared to placebo in patients with left ventricular systolic dysfunction who are hospitalized with acute heart failure. Cytokinetics expects results from ATOMIC-AHF will be announced in mid-year 2013. Cytokinetics also announced that dosing of patients has initiated in COSMIC-HF, or Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure. COSMIC-HF is a Phase II clinical trial designed to evaluate the pharmacokinetics, safety and efficacy of oral modified release formulations of omecamtiv mecarbil, in patients with chronic, stable heart failure and left ventricular systolic dysfunction.
News For CYTK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
10:18 EDTCYTKCytokinetics management to meet with JMP Securities
Subscribe for More Information
July 29, 2015
16:07 EDTCYTKCytokinetics sees FY15 reven, consensus $28.55M
16:06 EDTCYTKCytokinetics reports Q2 EPS (27c), consensus (24c)
Reports Q2 revenue $6.54M, consensus $7.32M. Reports cash, cash equivalents, and investments $108.2M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use